Entanglement Entropy of Annulus in Three Dimensions

The entanglement entropy of an annulus is examined in a three-dimensional system with or without a gap. For a free massive scalar field theory, we numerically calculate the mutual information across an annulus. We also study the holographic mutual information in the CGLP background describing a gapped field theory. We discover four types of solutions as the minimal surfaces for the annulus and classify the phase diagrams by varying the inner and outer radii. In both cases, we find the mutual information satisfies the monotonicity dictated by the unitarity and decays exponentially fast as the gap scale is increased. We speculate this is a universal behavior in any gapped system.Comment: 29 pages, 13 figures, v2: references added, minor change

A Holographic Proof of R\'enyi Entropic Inequalities

We prove R\'enyi entropic inequalities in a holographic setup based on the recent proposal for the holographic formula of R\'enyi entropies when the bulk is stable against any perturbation. Regarding the R\'enyi parameter as an inverse temperature, we reformulate the entropies in analogy with statistical mechanics, which provides us a concise interpretation of the inequalities as the positivities of entropy, energy and heat capacity. This analogy also makes clear a thermodynamic structure in deriving the holographic formula. As a by-product of the proof we obtain a holographic formula to calculate the quantum fluctuation of the modular Hamiltonian. A few examples of the capacity of entanglement are examined in detail.Comment: 29 pages, 1 figure; v3: references added, our assumption for the proof clarifie

Renormalized Entanglement Entropy on Cylinder

We develop a framework of calculating entanglement entropy for non-conformal field theories with the use of the dilaton effective action. To illustrate it, we locate a theory on a cylinder $\mathbb{R} \times \mathbb{S}^{2}$ and compute entanglement entropy of a cap-like region perturbatively with respect to the mass for a free massive scalar field. A renormalized entanglement entropy (REE) is proposed to regularize the ultraviolet divergence on the cylinder. We find that the REE decreases monotonically both in the small and large mass regions as the mass increases. We confirm all of these behaviors by the numerical calculations, which further shows the monotonic decrease of the REE in the entire renormalization group flow.Comment: 28 pages, 6 figures, v2: a new section on an interesting discrepancy added, some explanations clarifie

Chiral Polyurea with L-Lysinyl Residue Aimed for Optical Resolution

Novel polyurea was synthesized from lysinyl residue, L-lysine-4-nitroanilide Novel polyurea was synthesized from lysinyl residue, L-lysine-4-nitroanilide (L-Lys-4-NA) and 1,4-phenylene diisocyanate (1,4-PDI). The polyurea thus prepared gave durable self-standing membranes. The polyurea was converted into molecular recognition materials by using Z-D-Glu or Z-L-Glu as a print molecule. The Z-D-Glu molecularly imprinted membrane adsorbed the D-isomer of Glu in preference to the corresponding L-isomer and vice versa. Even though the polyurea consisted of L-lysinyl residue, both Z-D-Glu and Z-L-Glu worked as print molecules to construct molecular (chiral) recognition sites in the membrane. Those two types of molecularly imprinted membrane show chiral separation abilities, adopting a concentration gradient or an applied potential difference as a driving force for membrane transport

On Polygonal Square Triangular Numbers

A pentagonal square triangular number is a number which is a pentagonal number P5(ℓ), a square y2 and a triangular number P3(m) at the same time. It would be well known for the specialists that there exists no pentagonal square triangular number except for P3(1) = 12 = P5(1) = 1. But we don’t know any simple reference of the proof of this fact in print. The object of this note is to provide a such reference. Here we shall present three independent proofs of this fact one of which was already referred in the net article [24]

Effectiveness of mHealth consultation services for preventing postpartum depressive symptoms: a randomized clinical trial

妊娠中・産後にオンライン健康医療相談が利用できることで産後うつリスクが3分の2に低下. 京都大学プレスリリース. 2023-08-03.[Background] Although many conventional healthcare services to prevent postpartum depression are provided face-to-face, physical and psychosocial barriers remain. These barriers may be overcome by using mobile health services (mHealth). To examine the effectiveness of mHealth professional consultation services in preventing postpartum depressive symptoms in real-world settings, we conducted this randomized controlled trial in Japan, where universal free face-to-face perinatal care is available. [Methods] This study included 734 pregnant women living in Yokohama city who could communicate in Japanese, recruited at public offices and childcare support facilities. The participants were randomized to the mHealth group (intervention, n = 365), where they could use a free app-based mHealth consultation service with gynecologists/obstetricians, pediatricians, and midwives whenever and as many times as they wanted between 6 p.m. and 10 p.m. on weekdays throughout their pregnancy and postpartum periods (funded by the City of Yokohama government) or the usual care group (control, n = 369). The primary outcome was the risk of elevated postpartum depressive symptoms, defined as Edinburgh Postnatal Depression Scale score ≥ 9. Secondary outcomes were self-efficacy, loneliness, perceived barriers to healthcare access, number of clinic visits, and ambulance usage. All outcomes were collected three months post-delivery. We also conducted subgroup analyses assessing the differences in the treatment effect by sociodemographic status. [Results] Most women completed all questionnaires (n = 639 of 734, response rate: 87%). The mean baseline age was 32.9 ± 4.2 years, and 62% were primipara. Three months post-delivery, women in the mHealth group had a lower risk of elevated postpartum depressive symptoms (47/310 [15.2%]) compared to the usual care group (75/329 [22.8%], risk ratio: 0.67 [95% confidence interval: 0.48–0.93]). Compared with the usual care group, women in the mHealth group had higher self-efficacy, less loneliness, and fewer perceived barriers to healthcare access. No differences were observed in the frequency of clinic visits or ambulance usage. Furthermore, in the subgroup analyses, we did not find differences in the treatment effect by sociodemographic status. [Conclusions] Local government-funded mHealth consultation services have a preventive effect on postpartum depressive symptoms, removing physical and psychological barriers to healthcare access in real-world settings

cis9, trans11-Conjugated Linoleic Acid Differentiates Mouse 3T3-L1 Preadipocytes into Mature Small Adipocytes through Induction of Peroxisome Proliferator-activated Receptor γ

Dietary conjugated linoleic acid (CLA) has been reported to exhibit a number of therapeutic effects in animal models and patients, such as anti-hypertensive, anti-hyperlipidemic, anti-arteriosclerotic, anti-carcinogenic, and anti-diabetic effects. However, the underlying mechanism is not well-characterized. In the present study, the effects of cis(c)9, trans(t)11-CLA on the differentiation of mouse 3T3-L1 preadipocytes into mature adipocytes were examined. Treatment with c9, t11-CLA in the presence of insulin, dexamethasone, and 3-isobutyl-1-methyl-xanthine (differentiation cocktail) significantly stimulated the accumulation of triacylglycerol. The microscopic observation of cells stained by Oil Red O demonstrated that c9, t11-CLA increases the amount and proportion of small mature adipocytes secreting adiponectin, a benign adipocytokine, when compared to the differentiation cocktail alone. Furthermore, c9, t11-CLA increased bioactive peroxisome proliferator-activated receptor γ (PPARγ) levels in a nuclear extract of 3T3-L1 cells, suggesting the enhancing effect of this fatty acid on the nuclear transmission of PPARγ, a master regulator of adipocyte differentiation, in 3T3-L1 cells. These results suggest that the therapeutic effects of c9, t11-CLA on lifestyle-related diseases are partially due to the enhanced formation of small adipocytes from preadipocytes via PPARγ stimulation

The chimeric antibody chLpMab-7 targeting human podoplanin suppresses pulmonary metastasis via ADCC and CDC rather than via its neutralizing activity

Podoplanin (PDPN/Aggrus/T1α) binds to C-type lectin-like receptor-2 (CLEC-2) and induces platelet aggregation. PDPN is associated with malignant progression, tumor metastasis, and poor prognosis in several types of cancer. Although many anti-human PDPN (hPDPN) monoclonal antibodies (mAbs), such as D2-40 and NZ-1, have been established, these epitopes are limited to the platelet aggregation-stimulating (PLAG) domain (amino acids 29-54) of hPDPN. Recently, we developed a novel mouse anti-hPDPN mAb, LpMab-7, which is more sensitive than D2-40 and NZ-1, using the Cancer-specific mAb (CasMab) method. The epitope of LpMab-7 was shown to be entirely different from that of NZ-1, a neutralizing mAb against the PLAG domain according to an inhibition assay and lectin microarray analysis. In the present study, we produced a mouse-human chimeric anti-hPDPN mAb, chLpMab-7. ChLpMab-7 showed high antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Furthermore, chLpMab-7 inhibited the growth of hPDPN-expressing tumors in vivo. Although chLpMab-7 recognizes a non-PLAG domain of hPDPN, it suppressed the hematogenous metastasis of hPDPN-expressing tumors. These results indicated that chLpMab-7 suppressed tumor development and hematogenous metastasis in a neutralization-independent manner. In conclusion, hPDPN shows promise as a target in the development of a novel antibody-based therapy

Chimeric Anti-PDPN Antibody ChLpMab-2

Human podoplanin (hPDPN ), a platelet aggregation‐inducing transmembrane glycoprotein, is expressed in different types of tumors, and it binds to C‐type lectin‐like receptor 2 (CLEC ‐2). The overexpression of hPDPN is involved in invasion and metastasis. Anti‐hPDPN monoclonal antibodies (mAbs) such as NZ ‐1 have shown antitumor and antimetastatic activities by binding to the platelet aggregation‐stimulating (PLAG ) domain of hPDPN . Recently, we developed a novel mouse anti‐hPDPN mAb, LpMab‐2, using the cancer‐specific mAb (CasMab) technology. In this study we developed chLpMab‐2, a human–mouse chimeric anti‐hPDPN antibody, derived from LpMab‐2. chLpMab‐2 was produced using fucosyltransferase 8‐knockout (KO ) Chinese hamster ovary (CHO )‐S cell lines. By flow cytometry, chLpMab‐2 reacted with hPDPN ‐expressing cancer cell lines including glioblastomas, mesotheliomas, and lung cancers. However, it showed low reaction with normal cell lines such as lymphatic endothelial and renal epithelial cells. Moreover, chLpMab‐2 exhibited high antibody‐dependent cellular cytotoxicity (ADCC ) against PDPN ‐expressing cells, despite its low complement‐dependent cytotoxicity. Furthermore, treatment with chLpMab‐2 abolished tumor growth in xenograft models of CHO /hPDPN , indicating that chLpMab‐2 suppressed tumor development via ADCC . In conclusion, chLpMab‐2 could be useful as a novel antibody‐based therapy against hPDPN ‐expressing tumors